Prescription Drug Industry Case Study
As a lobbyist from Merck & Co drug compounding, I will evaluate such policies posed by the congress from budget committee. In 2000, our company spent over 160 million on advertising our new anti-inflammatory pain killer which was approved by the FDA a year ago. However, due to the new policy posed the federal government, we had to pull the drug off the market because false information in advertising process, this has caused huge financial difficulties for our company because of the lack of policy regulations, firstly, pharmaceutical companies spend most of their budget to get approval from FDA, and during the inspection period, every additional month could cost up to millions. As Baumgartner’s and Jones indicated, the image and venue of this specific policy is changing and will be changed in the near future, therefore, as a victim of this new advertising policy, we should receive funding regarding this policy. Nevertheless, if this was from S.1654, Overdose Prevention Act, it would dramatically reduce our production and sales for this pain reliever, because pain reliever are slightly addictive, therefore, this policy would grant more regulation for our production process and hurt our